Prostate Cancer Tumor Homograft Models

Despite the early approval of Sipuleucel-T for metastatic castration-resistant prostate cancer, subsequent progress in prostate cancer immunotherapy development has been limited. It is now generally accepted that we need to tackle prostate cancer by combinatiorial approaches, requiring highly relevant preclinical models for proof of principle efficacy evaluation. PTEN loss of function in the prostate epithelium is one of the central events in human prostate cancer, and activation of the MAPK pathway is often observed in advanced tumors. Our prostate homograft models feature these and other clinically-relevant mutations while retaining morphological similarity to human prostate cancer, thus ideally positioned to test novel combination regimens.

MODEL NUMBER ORIGINAL GEMM MUTATION # per page
mPR6003TRAMP (Pbsn-SV40T TGCLICK TO VIEW
mPR6065PTENFlox/Flox; P53-/-CLICK TO VIEW
mPR6066PTENFlox/Flox; P53-/-CLICK TO VIEW
mPR6135KRAS (G12D); PtenFlox/Flox;Probasin-creCLICK TO VIEW
mPR6189Probasin-cre,Pten flox/flox, Kras(G12D)CLICK TO VIEW
mPR6190Probasin-cre,Pten flox/flox, Kras(G12D)CLICK TO VIEW